{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:38:19Z","timestamp":1720694299050},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.reuma.2010.04.003","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T09:10:46Z","timestamp":1280999446000},"page":"21-24","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S2","title":["Bases patog\u00e9nicas de la terapia dirigida a las c\u00e9lulas B en el lupus eritematoso sist\u00e9mico (LES)"],"prefix":"10.1016","volume":"6","author":[{"given":"Jose Luis","family":"Pablos \u00c1lvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2010.04.003_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0162-3109(84)90048-1","article-title":"Effect of corticosteroids on serum antinuclear antibodies in man","volume":"8","author":"Weisbart","year":"1984","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.reuma.2010.04.003_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0889-857X(21)01003-6","article-title":"Intravenous cyclophosphamide therapy of severe SLE","volume":"15","author":"McCune","year":"1989","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reuma.2010.04.003_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000082103","article-title":"B lymphocyte depletion in rheumatoid arthritis: targeting of CD20","volume":"8","author":"Edwards","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.reuma.2010.04.003_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","article-title":"B-cell-directed therapies for autoimmune disease","volume":"5","author":"D\u00f6rner","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reuma.2010.04.003_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/ard.2007.075762","article-title":"Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls","volume":"67","author":"Jacobi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2010.04.003_bib6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.reuma.2010.04.003_bib7","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib8","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","article-title":"Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy","volume":"46","author":"Leandro","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2010.04.003_bib10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2010.04.003_bib11","doi-asserted-by":"crossref","unstructured":"Vital EM, Dass S, Rawstron AC, Buch MH, Go\u00ebb V, Henshaw K, et al. Management of non-response to rituximab in rheumatoid arthritis: Predictors and outcome of retreatment. Arthritis Rheum. 2010 Jan 25. [Epub ahead of print]","DOI":"10.1002\/art.27359"},{"key":"10.1016\/j.reuma.2010.04.003_bib12","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.reuma.2010.04.003_bib14","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib16","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.167.8.4710","article-title":"T cell activation in rheumatoid synovium is B cell dependent","volume":"167","author":"Takemura","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.reuma.2010.04.003_bib17","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham 3rd","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib19","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.reuma.2010.04.003_bib20","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall\u2019Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.reuma.2010.04.003_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2010.04.003_bib24","first-page":"1149","article-title":"Efficacy and Safety of Rituximab in Subjects with Active Proliferative Lupus Nephritis (LN): Results From the Randomized, Double-Blind Phase III LUNAR Study","volume":"60","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase ii, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2010.04.003_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10165-009-0213-x","article-title":"A perspective on B-cell-targeting therapy for SLE","volume":"20","author":"Looney","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reuma.2010.04.003_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.reuma.2010.04.003_bib28","doi-asserted-by":"crossref","unstructured":"Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010 Feb 3. [Epub ahead of print]","DOI":"10.1182\/blood-2009-07-229815"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X10001324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X10001324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T16:03:14Z","timestamp":1635955394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X10001324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":28,"alternative-id":["S1699258X10001324"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2010.04.003","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}